Journal
CELL METABOLISM
Volume 19, Issue 3, Pages 373-379Publisher
CELL PRESS
DOI: 10.1016/j.cmet.2014.01.001
Keywords
-
Categories
Funding
- NIH [GM51405, CA46595]
Ask authors/readers for more resources
The mammalian target of rapamycin (mTOR) signaling pathway is a master regulator of cell growth and metabolism. Deregulation of the mTOR pathway has been implicated in a number of human diseases such as cancer, diabetes, obesity, neurological diseases, and genetic disorders. Rapamycin, a specific inhibitor of mTOR, has been shown to be useful in the treatment of certain diseases. Here we discuss its mechanism of action and highlight recent findings regarding the effects and limitations of rapamycin monotherapy and the potential utility of combination therapy with rapamycin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available